Tagged: Sleep Review

Blue Cross Blue Shield Association’s Evidence Street Issues Positive Assessment for Inspire Therapy 0

Blue Cross Blue Shield Association’s Evidence Street Issues Positive Assessment for Inspire Therapy

Inspire Medical Systems Inc, a medical technology company that makes an implantable therapy for obstructive sleep apnea (OSA) and is focused on the development and commercialization of minimally invasive solutions for patients with the sleep disorder, reports that the Blue Cross Blue Shield Association’s (BCBSA) Evidence Street issued a positive assessment of Inspire therapy to its members. BCBSA is a national federation of 36 Blue Cross and Blue Shield (BCBS) companies.

The report summarized that sufficient evidence exists to determine that hypoglossal nerve stimulation results in a meaningful improvement in the net health outcome for patients meeting the following selection criteria, which are based on information from clinical study populations and clinical expert opinion:

  • age ≥ 22 years in adults, or adolescents with Down’s syndrome (age 10 to 21 years); and
  • diagnosed moderate to severe OSA (with less than 25% central apneas); and
  • CPAP failure or inability to tolerate CPAP; and
  • body mass index ≤ 35 kg/m2 in adults; and
  • favorable pattern of palatal collapse.

“This positive assessment demonstrates the strength of the clinical evidence for Inspire therapy and is

Learning to Live with CPAP Machine to Treat Sleep Apnea Not an Easy Adjustment 0

Learning to Live with CPAP Machine to Treat Sleep Apnea Not an Easy Adjustment

A new CPAP user has trouble with the device “pumping forced air into [her] stomach,” reports the Orlando Sentinel.

On the other hand, this user’s nocturnal musings about the machine would be far more kindly if the humidifier were filled nightly with Cabernet.

Read the full commentary at orlandosentinel.com

from Sleep Review http://www.sleepreviewmag.com/2019/01/learning-live-cpap-machine-treat-sleep-apnea-not-easy-adjustment/…

Celebrate World Sleep Day on March 15: Healthy Sleep, Healthy Aging 0

Celebrate World Sleep Day on March 15: Healthy Sleep, Healthy Aging

World Sleep Society is issuing a global call to action about the importance of healthy sleep. Friday, March 15, 2019 is the 12th annual World Sleep Day. Created and hosted by World Sleep Society, World Sleep Day is an internationally recognized awareness event bringing researchers, health professionals, and patients together to recognize sleep and its important impact on our health.

World Sleep Day 2019 will incorporate the slogan, “Healthy Sleep, Healthy Aging,” intended to emphasize the importance of sleep in overall health at any age. This focus is purposefully broad in meaning, surrounding the message that quality of life can be improved with healthy sleep. Conversely, when sleep fails, health declines, decreasing quality of life. Sound sleep is a treasured function and one of the core pillars of health. World Sleep Society has compiled 10 tips for healthier sleep.

From the Mayo Clinic Center for Sleep Medicine

Erik St. Louis, MD, co-director of the Mayo Center for Sleep Medicine in Rochester, Minn, emphasizes this year’s theme of Healthy Sleep, Healthy Aging by explaining, “For most adults, getting 7 to

ProSomnus Selected to Present at Digital Medicine and MedTech Showcase 0

ProSomnus Selected to Present at Digital Medicine and MedTech Showcase

ProSomnus Sleep Technologies has been selected to present at the Digital Medicine and MedTech Showcase, Jan 7-9, 2019, in San Francisco. This annual event is a forum that connects leaders in medicine with companies that are developing novel technologies to address important healthcare issues.

In a release, ProSomnus states it will utilize the opportunity to raise awareness of obstructive sleep apnea (OSA) and how the company is using technology to enable better therapy.

“Obstructive sleep apnea is a large, rapidly growing, public health issue that is largely unaddressed,” says Len Liptak, CEO and co-founder of ProSomnus Sleep Technologies, in a release. “To scale this issue, OSA therapies need to be effective for everyday use, easy to prescribe, and economical. ProSomnus sleep devices are designed to help patients and providers achieve these goals.”

ProSomnus will discuss how digital manufacturing technologies are utilized to produce precision medical devices that are customized to the anatomy and prescription for each and every patient.

“OSA is a medical condition, diagnosed by a medical doctor, where dentists are the DME [durable medical equipment] provider. ProSomnus devices

ResApp Submits CE Mark Technical File for Acute Respiratory Disease Diagnostic Smartphone Application 0

ResApp Submits CE Mark Technical File for Acute Respiratory Disease Diagnostic Smartphone Application

ResApp Health Ltd, a digital health company developing smartphone applications for the diagnosis and management of respiratory disease, has submitted its CE Mark Technical File to its European Notified Body, the British Standards Institution (BSI), for a smartphone application for the diagnosis of acute pediatric respiratory disease. ResAppDx-EU is a mobile software application to be used by clinicians for the diagnosis of lower respiratory tract disease, croup, pneumonia, asthma/reactive airway disease, and bronchiolitis in infants and children. CE Marking will enable the commercial sale of ResAppDx-EU in the European Economic Area and facilitate commercialization in other markets such as Australia, Canada, and Singapore.

“The preparation and filing of the CE Mark Technical File for ResAppDx-EU, our flagship acute respiratory disease diagnostic tool, is an exciting moment for ResApp as it unlocks the last element required to commercialize our first product,” says Tony Keating, CEO and managing director, in a release. “Europe represents a very attractive opportunity with a large portion of the continent’s 6 billion annual general practitioner visits related to respiratory disease. ResAppDx-EU will provide clinicians with the first

Oral Appliance Maker Signs Deal with Pro Player Health Alliance 0

Oral Appliance Maker Signs Deal with Pro Player Health Alliance

Oral appliance maker Vivos Therapeutics has signed a partnership with Pro Player Health Alliance, a provider in the National Football League Players Association’s Professional Athletes Foundation (PAF) sleep apnea research program.

The Vivos System consists of multidisciplinary therapeutic protocols and oral appliances that remodel and enhance the airway. Vivos will participate in the NFLPA’s Professional Athletes Foundation’s health and wellness checkup events that along with a full cardiovascular evaluation also focuses on breathing wellness. Events will take place in NFL team cities and at the 2019 Pro Bowl and Super Bowl.

“Sleep apnea is a serious and growing health epidemic facing America,” says Edward Loew, SVP of capital markets and strategic initiatives at Vivos, in a release. “Our newly formed partnership with Pro Player Health Alliance will allow us to provide highly effective relief to former NFL players, who are a high-risk segment of the population.”

David Gergen, CEO of Pro Player Health Alliance, says, “Pro Player Health Alliance is pleased to showcase the Vivos System to NFL greats and top-notch dentists around the country.”

Through co-sponsored health and wellness

Improving Sleep Quality in Parkinson’s: Is Levodopa-Carbidopa Intestinal Gel Effective? 0

Improving Sleep Quality in Parkinson’s: Is Levodopa-Carbidopa Intestinal Gel Effective?

New research found that patients with advanced Parkinson’s disease who were treated with levodopa-carbidopa intestinal gel infusion experienced an improvement in sleep quality, according to a review published in Parkinson’s Disease.

The study sample included 7 consecutive participants who received an implant for continuous levodopa-carbidopa intestinal gel infusion; dosage was titrated individually until greatest motor control was attained. The investigators performed overnight polysomnography before and after 6 months of treatment, reporting on parameters including sleep efficiency, wake after sleep onset, REM sleep and non-REM sleep, snoring sounds, apnea-hypopnea index, arousals, leg movements in sleep, and more. The investigators also administered questionnaires at baseline and follow-up, including the Epworth Sleepiness Scale, fatigue scale, Pittsburgh Sleep Quality Index, Beck Depression Inventory, and the Hamilton Anxiety Rating Scale.

Motor fluctuations and symptoms showed significant improvement after 6 months of continuous levodopa-carbidopa intestinal gel infusion. Polysomnography results showed improvements in generalized sleep efficiency; however, changes observed in sleep parameters from baseline to follow-up were not considered statistically significant.

Get the full story at www.neurologyadvisor.com

from Sleep Review http://www.sleepreviewmag.com/2018/12/sleep-quality-parkinsons-levodopa-carbidopa-intestinal-gel/…

Study Finds Risk Factors for REM Sleep Behavior Disorder 0

Study Finds Risk Factors for REM Sleep Behavior Disorder

Taking antidepressants for depression, having post-traumatic stress disorder (PTSD), or anxiety diagnosed by a doctor are risk factors for rapid eye movement (REM) sleep behavior disorder. This is according to a study published in the Dec 26, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology. The study also found men are more likely to have the disorder.

REM sleep is the dream state of sleep. During normal REM sleep, your brain sends signals to prevent your muscles from moving. However, for people with REM sleep behavior disorder, those signals are disrupted. A person may act out violent or action-filled dreams by yelling, flailing their arms, punching, or kicking, to the point of harming themselves or a sleep partner.

“While much is still unknown about REM sleep behavior disorder, it can be caused by medications or it may be an early sign of another neurologic condition like Parkinson’s disease, dementia with Lewy bodies or multiple system atrophy,” says study author Ronald Postuma, MD, MSc, of McGill University in Montreal, Canada, and a member of

Reporting “Vivid Dreams” Linked with Shorter Time to Narcolepsy Diagnosis 0

Reporting “Vivid Dreams” Linked with Shorter Time to Narcolepsy Diagnosis

A Nexus Narcolepsy Registry study links specific factors to diagnosis delays.

In 2015, to better understand narcolepsy, patient advocacy organizations, researchers, and others created the Nexus Narcolepsy Registry, an online database that tracks a large number of people with the rare neurological sleep disorder narcolepsy over time.

Anyone who is a narcolepsy patient can share his or her data anonymously through questionnaires and surveys so researchers can glean more insight on how the condition affects patients. This can range from information on which symptoms the participants experience to how long it takes for them to receive a correct diagnosis.

In 2018, researchers published a study titled, “Predictors of Time to Narcolepsy Diagnosis in Participants With Adult Onset of Symptoms: Results From the Nexus Narcolepsy Registry,” that looked to determine the factors that are associated with delays in seeking evaluation and diagnosis among adult patients with narcolepsy.

“We found that there was a significant delay in diagnosis for patients who have experienced narcolepsy symptoms since they were children,” says Michael Thorpy, MD, director of the

SomnoMed Closes All Renew Sleep Solutions Locations 0

SomnoMed Closes All Renew Sleep Solutions Locations

The subsidiary marketed directly to sleep apnea patients for about two years, but now the company returns to its core business model.

SomnoMed stepped off the beaten path with its Renew Sleep Solutions direct-to-consumer business model. But instead of blazing a new trail that other sleep medicine therapy companies may have followed, the Australian oral appliance maker is now retreating from what was, in hindsight, a costly and bumpy detour. Renew Sleep Solutions (RSS), SomnoMed’s direct-to-consumer subsidiary that launched at the end of 2016, will be closing all of its sleep centers by January 1, 2019. SomnoMed will be navigating back to its core business model, focusing its United States’ efforts on the more traditional medical referral pathways.

In tandem, the company made a leadership change. Derek Smith, who served as CEO from Sept 1, 2016, stepped down, effective Nov 16, 2018, as SomonMed no longer needs a US-based CEO. On Nov 19, Neil Verdal-Austin, who had been SomnoMed’s chief financial officer since Oct 2008, became SomnoMed CEO. Verdal-Austin also previously managed SomoMed’s Asia-Pacific region.

Sleep